Consensus Galecto, Inc.

Equities

GLTO

US36322Q1076

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
0.68 ^USD	-0.01%		-4.24%	-5.56%

May. 01	Galecto, Inc. Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab	CI
Apr. 29	Galecto, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Galecto, Inc.

Price target over the last 5 years

History of analyst recommendation changes

dbef57d8454e255ceca6c2f.9lDLK6UZtm6eVpUKTCWHG_wtMlkVrPiYuTI9H-6R8Wk.rAq-auNb-ALoNf9le3DYNq9PRzdwwMnX3V5nUJjYsA6yErhJ8kODW8Qn5g~d29ead499039766a5b3667782017b53a

Analyst Recommendations on Galecto, Inc.

HC Wainwright Downgrades Galecto to Neutral From Buy	23-09-28	MT
HC Wainwright Adjusts Price Target on Galecto to $2 From $12, Maintains Buy Rating	23-08-21	MT
Oppenheimer Initiates Coverage on Galecto With Outperform Rating, $12 Price Target	23-06-20	MT
Cantor Fitzgerald Initiates Galecto at Overweight With $16 Price Target	23-03-17	MT
SVB Securities Adjusts Galecto's Price Target to $13 from $16, Keeps Outperform Rating	22-08-03	MT
Credit Suisse Trims Galecto's Price Target to $6 from $7, Maintains Outperform Rating	22-02-14	MT
GALECTO : Credit Suisse Lowers Galecto's PT to $7 from $12 on Lower Projected Sales for GB0139, Reduced Near-Term M&A Expectations; Keeps Outperform Rating	21-08-06	MT
GALECTO : Credit Suisse Lowers Galecto's PT to $12 from $29 After Recommendation to End Parts of GB0139 Phase 2 Study, Keeps Outperform Rating	21-03-16	MT
GALECTO : SVB Leerink Adjusts Galecto's Price Target to $16 From $27, Keeps Outperform Rating	21-03-16	MT
GALECTO : Credit Suisse Initiates Coverage on Galecto With Outperform Rating, $29 Price Target	20-11-23	MT
GALECTO : BofA Securities Initiates Coverage on Galecto With Buy Rating, $21 Price Target	20-11-23	MT
GALECTO : SVB Leerink Starts Galecto at Outperform With $27 Price Target	20-11-23	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.68 USD

Average target price

6 USD

Spread / Average Target

+782.35%

High Price Target

10 USD

Spread / Highest target

+1,370.59%

Low Price Target

2 USD

Spread / Lowest Target

+194.12%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Galecto, Inc.

HC Wainwright
Oppenheimer
Cantor Fitzgerald
SVB Securities LLC
Credit Suisse
SVB Leerink

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar